Literature DB >> 9690703

Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine.

A Dallal, G Chouinard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9690703     DOI： 10.1097/00004714-199808000-00017

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  6 in total

1.  A case of interdose discontinuation symptoms with venlafaxine extended release.

Authors:  Joseph Petit; Randy A Sansone
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 3.  Venlafaxine extended-release: a review of its use in the management of major depression.

Authors:  K Wellington; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Challenges of a mechanistic feedback model describing nicotinic acid-induced changes in non-esterified fatty acids in rats.

Authors:  Christine Ahlström; Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-07-04       Impact factor: 2.745

Review 5.  Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Authors:  Jacob P R Jacobsen; Andrew D Krystal; K Ranga R Krishnan; Marc G Caron
Journal:  Trends Pharmacol Sci       Date:  2016-09-28       Impact factor: 14.819

6.  Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy.

Authors:  Richard C. Shelton
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.